Sunshine Biopharma, Inc. (SBFM) 股票分析

公司概述

Sunshine Biopharma, Inc. operates as a pharmaceutical entity dedicated to the research and development of life-saving medicines across various therapeutic areas, with a specific focus on oncology and antivirals within the United States and Canadian markets. The company functions within the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, positioning itself as a provider of essential prescription generic pharmaceuticals and nonprescription products. In terms of scale, the company possesses a market capitalization of $5.15M and generated annual revenue of $36.31M, though specific employee count data is not available in the current dataset. These financial metrics indicate that the company maintains a relatively small market presence, characterized by a low market capitalization relative to its revenue generation, which suggests a niche operational footprint typical of specialty drug manufacturers focusing on specific therapeutic verticals rather than broad-market volume sales.

财务健康

The company reported a total revenue of $36.31M over the trailing twelve months, while recording a net income of $-5,975,352 and an EBITDA of $-4,146,712. The substantial disparity between the positive revenue figure and the significantly negative net income reveals a cost structure where operating expenses and research costs heavily outweigh gross profits, resulting in a bottom-line loss. Free cash flow stood at $-4,632,801, indicating that the company is currently burning cash, which limits immediate financial flexibility and necessitates reliance on existing cash reserves to fund operations and development activities. Profitability is constrained across all levels, with a gross margin of 33.8%, an operating margin of -19.3%, and a profit margin of -16.5%, illustrating that while production costs are controlled relative to sales, high overheads or R&D expenditures are eroding overall profitability. The balance sheet shows a cash position of $9.12M against total debt of $812,422, yet the debt-to-equity ratio is elevated at 3.53, suggesting a leveraged capital structure despite the low absolute debt amount. Liquidity is robust in the short term, evidenced by a current ratio of 4.17, which implies the company holds sufficient current assets to cover short-term obligations comfortably. However, return metrics remain negative, with a return on equity of -25.7% and a return on assets of -9.2%, revealing that management effectiveness in generating returns on investor capital and asset base is currently hindered by the company's developmental stage and ongoing losses.

估值评估

Valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is calculated at 0.01, implying that the market prices in future earnings expectations that differ from historical performance or that current losses are expected to persist. The price-to-book ratio stands at 0.20, indicating that the market values the company at a significant discount to its book value, which often reflects high uncertainty regarding future cash flows and the potential dilution of assets if the company fails to achieve profitability. Alternative valuation multiples such as a price-to-sales ratio of 0.14 and an EV/EBITDA of 0.76 suggest that the market assigns very low value to the company's revenue and earnings potential relative to its size. The stock has traded between a 52-week high of $2.43 and a 52-week low of $1.00, and without a specific current price provided in the facts, the valuation context relies on these historical bounds to define the range of investor sentiment volatility. The beta value of 1.60 indicates that the stock exhibits significantly higher price volatility relative to the broader market, meaning price movements are amplified compared to the general market index. These combined metrics suggest a high-risk valuation profile where the market prices in deep uncertainty about the path to profitability.

Growth & Income

Revenue growth year-over-year declined by 10.6%, while earnings growth is not applicable due to the lack of prior period profitability, indicating that the company is not currently in a growth phase driven by expanding earnings but rather by navigating a period of contraction or stabilization. Since the company is not a dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders, which implies that any generated cash or retained earnings are being reinvested into research and development rather than returned to investors. The overall growth and income profile is characterized by negative revenue momentum and an absence of dividend income, reflecting the typical lifecycle of a pre-revenue or early-stage pharmaceutical firm focused on R&D expenditures. This profile highlights a company that prioritizes long-term therapeutic development over short-term financial returns or income distribution to its shareholder base.